Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Date:4/2/2009

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"We are excited about these early results that confirm the predictive capability of our repositioning platform technology and encourage us to further develop this compound in a disease area where there is a significant need for new therapies" said Aris Persidis, Ph.D., President of Biovista. "What is also encouraging is that we reached this stage just 4 months after deciding to work in MS. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company" Dr. Persidis added.

About Biovista's BVA-101 trial in the MS EAE-MOG model

MS is a chronic inflammatory disease of the CNS with unknown etiology. It is the most frequent non-traumatic disabling neurologic disease among young adults, with 12,000 new diagnoses per year in the US alone, and over 2.5 million patients worldwide. In the animal proof of concept trial, BVA-101 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-101 induced a statistically significant reduction of EAE severity, the magnitude of which was statistically similar to that caused by dexamethasone.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commerci
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® today ... Caris Molecular Intelligence®, the company,s panomic, comprehensive tumor ... between several rare and difficult to treat gynecological ... the potential to improve patient outcomes. These studies ... the Society of Gynecologic Oncology (SGO) 2015 Annual ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
(Date:3/27/2015)... Working in collaboration with the National Amyloidosis Centre ... , Richmond Pharmacology is the first centre worldwide to dose ... investigational RNAi therapeutic being developed for the treatment of transthyretin-mediated ... Read press release ... Georges University of London , Richmond Pharmacology ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 PRC ... (CRO), announced today several management and executive appointments effective ... Chief Financial Officer (CFO) and member of the Board ... of Business Operations, and Sue Dowden will assume the ... co-founder and current Chief Operations Officer (COO), has been ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... Pennsylvania have theorized a way to increase the speed ... tiny metal particles to well past the speed of ... this theory would use nanosized metal chains as building ... operate at higher frequencies than conventional electronic circuits. ...
... Signed in Fourth Quarter, SUNNYVALE, Calif., Aug. 19 ... in the field of radiosurgery,announced today financial results for ... For the fourth quarter of fiscal 2008, Accuray ... over fourth quarter of fiscal 2007,total revenue of $44.0 ...
... Aug. 19 Bill Pollock, president and CEO,of ... and,non-personal-delivered messages and solutions for the biopharmaceutical,industry, has ... the 100 most,inspiring and influential leaders in the ... four companies within the Publicis Healthcare,Communications Group., ...
Cached Biology Technology:University of Pennsylvania scientists move optical computing closer to reality 2University of Pennsylvania scientists move optical computing closer to reality 3Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 2Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 3Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 4Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 5Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 6Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 7Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 8Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008 9Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 2Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 3
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... from Nanyang Technological University (NTU) has yielded important breakthroughs on ... treatments for aging, obesity and diabetes. The study found ... body, muscle loss due to aging or illnesses can be ... to go into a ,fat-burning mode, which will fight obesity ...
... the Department of Health Policy and Management at ... impact of pollution on agricultural worker productivity using ... that ozone, even at levels below current air-quality ... significant negative impacts on worker productivity. Their findings ...
... a new principle for fighting bacterial infections, in other words, ... . The new antibiotic mechanism is based on selectively blocking ... the growth of certain bacteria. Scientists hope to be able ... , Much work remains to be done, but we believe ...
Cached Biology News:NTU study finds ways to prevent muscle loss, obesity and diabetes 2NTU study finds ways to prevent muscle loss, obesity and diabetes 3Ozone levels have sizeable impact on worker productivity 2Antibiotics based on a new principle may defeat MRSA 2Antibiotics based on a new principle may defeat MRSA 3
Request Info...
... Clean spin filters allow for the rapid isolation ... your DNA gel slice in the spin filter, ... your DNA is recovered. There is no need ... buffers. Spin filters can also be used for ...
Request Info...
...
Biology Products: